KalVista Pharmaceuticals (KALV) Competitors

KalVista Pharmaceuticals (NASDAQ:KALV) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Which has better valuation and earnings, KALV or RXRX?

KalVista Pharmaceuticals has higher earnings, but lower revenue than Recursion Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	N/A	N/A	-$183.44M	-$3.69	-3.54
Recursion Pharmaceuticals	$58.84M	35.67	-$463.66M	-$1.78	-2.72

Do analysts rate KALV or RXRX?

KalVista Pharmaceuticals currently has a consensus price target of $26.29, suggesting a potential upside of 100.99%. Recursion Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 44.78%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Is KALV or RXRX more profitable?

KalVista Pharmaceuticals has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Recursion Pharmaceuticals' return on equity of -76.09% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-134.07%	-82.65%
Recursion Pharmaceuticals	-1,004.91%	-76.09%	-54.29%

Which has more risk and volatility, KALV or RXRX?

KalVista Pharmaceuticals has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Do insiders & institutionals hold more shares of KALV or RXRX?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor KALV or RXRX?

In the previous week, Recursion Pharmaceuticals had 7 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 6 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.00 beat Recursion Pharmaceuticals' score of 0.73 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Recursion Pharmaceuticals beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks.